Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease.

Lin, Joseph H; Zhang, Jenny J; Lin, Shao-Lee; Chertow, Glenn M

Lin, Joseph H; Zhang, Jenny J; Lin, Shao-Lee; Chertow, Glenn M.

Nephron ; 129(1): 29-33, 2015.

Article in En | MEDLINE | ID: mdl-25531162

Subject(s)

Diabetic Nephropathies/drug therapy; MAP Kinase Kinase Kinase 5/antagonists & inhibitors; Adult; Aged; Albuminuria/drug therapy; Albuminuria/metabolism; Angiotensin II Type 1 Receptor Blockers/administration & dosage; Angiotensin-Converting Enzyme Inhibitors/administration & dosage; Diabetes Mellitus, Type 2/complications; Diabetic Nephropathies/physiopathology; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate/drug effects; Humans; Male; Middle Aged; Oxidative Stress/drug effects; Protein Kinase Inhibitors/administration & dosage; Protein Kinase Inhibitors/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: MAP Kinase Kinase Kinase 5 / Diabetic Nephropathies Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Nephron Year: 2015 Type: Article

Fulltext

XML

PubMed Links

Search on Google